亨廷顿病

Walker FO. Huntington's disease. Lancet. 2007 Jan 20;369(9557):218-28.

• 摘要

Hayden MR. Huntington's chorea. New York, NY: Springer; 1981.

Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord. 2008 Aug 15;23(11):1491-504.

• 摘要

Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother. 2007 Feb;8(2):141-53.

• 摘要

Novak MJ, Tabrizi SJ. Huntington's disease. BMJ. 2010 Jun 30;340:c3109.

• 摘要

Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986 Feb;36(2):244-9.

• 摘要

Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96.

• 摘要

Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20.

• 摘要

1.  Walker FO. Huntington's disease. Lancet. 2007 Jan 20;369(9557):218-28.

• 摘要

2.  Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature. J Child Neurol. 2006 Mar;21(3):223-9.

• 摘要

3.  Harper PS. The epidemiology of Huntington's disease. Hum Genet. 1992 Jun;89(4):365-76.

• 摘要

4.  Hayden MR. Huntington's chorea. New York, NY: Springer; 1981.

5.  Rawlins M. Huntington's disease out of the closet? Lancet. 2010 Oct 23;376(9750):1372-3.

• 摘要

6.  Folstein S. Huntington's disease: a disorder of families. Baltimore, MD: Johns Hopkins University Press; 1989.

7.  Pridmore SA. The large Huntington's disease family of Tasmania. Med J Aust. 1990 Nov 19;153(10):593-5.

• 摘要

8.  Harper PS, Jones L. Huntington's disease: genetic and molecular studies. In: Bates G, Harper P, Jones L, eds. Huntington's disease. New York: Oxford University Press; 2002:113-58.

9.  Wright HH, Still CN, Abramson RK. Huntington's disease in black kindreds in South Carolina. Arch Neurol. 1981 Jul;38(7):412-4.

• 摘要

10.  Wanker E, Dröge A. Structural biology of Huntington's disease. In: Bates G, Harper P, Jones L, eds. Huntington's disease. New York: Oxford University Press; 2002:327-47.

11.  Marchut AJ, Hall CK. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations. Proteins. 2007 Jan 1;66(1):96-109.

• 摘要

12.  Oliveira JM, Jekabsons MB, Chen S, et al. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem. 2007 Apr;101(1):241-9.

• 摘要

13.  Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta. 2006 Mar;1762(3):373-80.

• 摘要

14.  Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006 Jun 16;125(6):1179-91.

• 摘要

15.  Peng Q, Masuda N, Jiang M, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol. 2008 Mar;210(1):154-63.

• 摘要

16.  Stober T, Wussow W, Schimrigk K. Bicaudate diameter: the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology. 1984;26(1):25-8.

• 摘要

17.  Gutekunst C, Norflus F, Hersch S. The neuropathology of Huntington's disease. In: Bates G, Harper P, Jones L, eds. Huntington's disease. New York: Oxford University Press; 2002:251-75.

18.  Cepeda C, Wu N, André VM, et al. The corticostriatal pathway in Huntington's disease. Prog Neurobiol. 2007 Apr;81(5-6):253-71.

• 全文
• 摘要

19.  Bean L, Bayrak-Toydemir P; American College of Medical Genetics and Genomics. Standards and guidelines for clinical genetics laboratories, 2014 edition: technical standards and guidelines for Huntington disease. Genet Med. 2014 Dec;16(12):e2.

• 全文
• 摘要

20.  Li JL, Hayden MR, Warby SC, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet. 2006 Aug 17;7:71.

• 全文
• 摘要

21.  van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):441-8.

• 摘要

22.  Walker FO. Huntington's disease. Semin Neurol. 2007 Apr;27(2):143-50.

• 摘要

23.  Andrich J, Saft C, Ostholt N, et al. Assessment of simple movements and progression of Huntington's disease. J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):405-7.

• 摘要

24.  Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol. 2007 Jan;64(1):116-21.

• 全文
• 摘要

25.  Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):219-26.

• 摘要

26.  Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci. 2005 Fall;17(4):496-502.

• 摘要

27.  Tibben A, Vegter-vd Vlis M, vd Niermeijer MF, et al. Testing for Huntington's disease with support for all parties. Lancet. 1990 Mar 3;335(8688):553.

• 摘要

28.  Tibben A. Genetic counseling and presymptomatic testing. In: Bates G, Harper P, Jones L, eds. Huntington's disease. New York: Oxford University Press; 2002:198-250.

29.  MacLeod R, Tibben A, Frontali M, et al; Editorial Committee and Working Group ‘Genetic Testing Counselling’ of the European Huntington Disease Network. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet. 2013 Mar;83(3):221-31.

• 摘要

30.  Losekoot M, van Belzen MJ, Seneca S, et al; European Molecular Genetic Quality Network (EMQN). EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. Eur J Hum Genet. 2013 May;21(5):480-6.

• 全文
• 摘要

31.  Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology. 2006 Aug 8;67(3):394-9.

• 摘要

32.  Gordon AM, Quinn L, Reilmann R, et al. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol. 2000 May;163(1):136-48.

• 摘要

33.  Hoff JI, van Hilten BJ, Roos RA. A review of the assessment of dyskinesias. Mov Disord. 1999 Sep;14(5):737-43.

• 摘要

34.  Burke JR, Wingfield MS, Lewis KE, et al. The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet. 1994 Aug;7(4):521-4.

• 摘要

35.  Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol. 2004 Aug;56(2):299-302.

• 摘要

36.  Breedveld GJ, Percy AK, MacDonald ME, et al. Clinical and genetic heterogeneity in benign hereditary chorea. Neurology. 2002 Aug 27;59(4):579-84.

• 摘要

37.  Schrag A, Quinn NP, Bhatia KP, et al. Benign hereditary chorea - entity or syndrome? Mov Disord. 2000 Mar;15(2):280-8.

• 摘要

38.  Hewer E, Danek A, Schoser BG, et al. McLeod myopathy revisited: more neurogenic and less benign. Brain. 2007 Dec;130(Pt 12):3285-96.

• 摘要

39.  Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain. 2003 Jul;126(Pt 7):1599-603.

• 全文
• 摘要

40.  Schöls L, Bauer P, Schmidt T, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004 May;3(5):291-304.

• 摘要

41.  Laplanche JL, Hachimi KH, Durieux I, et al. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain. 1999 Dec;122 ( Pt 12):2375-86.

• 全文
• 摘要

42.  Al-Tahan AY, Divakaran MP, Kambouris M, et al. A novel autosomal recessive 'Huntington's disease-like' neurodegenerative disorder in a Saudi family. Saudi Med J. 1999 Jan;20(1):85-9.

• 摘要

43.  Kambouris M, Bohlega S, Al-Tahan A, et al. Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet. 2000 Feb;66(2):445-52.

• 全文
• 摘要

44.  Hartig MB, Hörtnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol. 2006 Feb;59(2):248-56.

• 摘要

45.  Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007 Jan;130(Pt 1):110-9.

• 全文
• 摘要

46.  Isaacs JD, Rakshi J, Baker R, et al. Chorea associated with thyroxine replacement therapy. Mov Disord. 2005 Dec;20(12):1656-7.

• 摘要

47.  Dike GL. Chorea gravidarum: a case report and review. Md Med J. 1997 Sep;46(8):436-9.

• 摘要

48.  Cardoso F, Eduardo C, Silva AP, et al. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord. 1997 Sep;12(5):701-3.

• 摘要

49.  Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis. 1998 Aug;57(8):456-9.

• 全文
• 摘要

50.  Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore). 1997 May;76(3):203-12.

• 摘要

51.  Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: report of 119 cases. Mov Disord. 2006 Dec;21(12):2192-6.

• 摘要

52.  Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979 Jan;29(1):1-3.

• 摘要

53.  Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996 Mar;11(2):136-42.

• 摘要

54.  Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord. 2008 Aug 15;23(11):1491-504.

• 摘要

55.  Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother. 2007 Feb;8(2):141-53.

• 摘要

56.  Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008 Apr;5(2):181-97.

• 摘要

57.  Novak MJ, Tabrizi SJ. Huntington's disease. BMJ. 2010 Jun 30;340:c3109.

• 摘要

58.  Priller J, Ecker D, Landwehrmeyer B, et al. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord. 2008 Sep 15;23(12):1788.

• 摘要

59.  Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006456.

• 全文
• 摘要

60.  Mestre TA, Ferreira JJ. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord. 2012 May;18(4):316-20.

• 摘要

61.  Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother. 2003 Mar;37(3):452.

• 摘要

62.  Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Br J Psychiatry. 1986 Nov;149:654-6.

• 摘要

63.  Folstein S, Abbott MH, Chase GA, et al. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med. 1983 Aug;13(3):537-42.

• 摘要

64.  Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington's disease. J Neuropsychiatry Clin Neurosci. 1994 Spring;6(2):154-9.

• 摘要

65.  Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington's disease. J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):209-10.

• 摘要

66.  Beale MD, Kellner CH, Gurecki P, et al. ECT for the treatment of Huntington's disease: a case study. Convuls Ther. 1997 Jun;13(2):108-12.

• 摘要

67.  van Duijn E, Roos RA, Smarius LJ, et al. Electroconvulsive therapy in patients with Huntington's disease and depression [in Dutch]. Ned Tijdschr Geneeskd. 2005 Sep 24;149(39):2141-4.

• 摘要

68.  Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics. 1997 Jul-Aug;38(4):389-91.

• 摘要

69.  Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry. 1994 Jul;151(7):1097.

• 摘要

70.  Royuela Rico A, Gil-Verona JA, Macías Fernández JA. A case of obsessive symptoms in Huntington's disease [in Spanish]. Actas Esp Psiquiatr. 2003 Nov-Dec;31(6):367-70.

• 摘要

71.  De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington's disease. Psychopharmacology (Berl). 2001 Jan 1;153(2):264-6.

• 摘要

72.  Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand. 2002 Jun;105(6):441-4.

• 摘要

73.  Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):69-72.

• 摘要

74.  Lipe H, Schultz A, Bird TD. Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am J Med Genet. 1993 Dec 15;48(4):231-3.

• 摘要

75.  Anderson KE, Marshall FJ. Behavioral symptoms associated with Huntington's disease. Adv Neurol. 2005;96:197-208.

• 摘要

76.  European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. EMA/145600/2018. March 2018 [internet publication].

• 全文

77.  Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust N Z J Psychiatry. 1975 Jun;9(2):115-8.

• 摘要

78.  Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986 Feb;36(2):244-9.

• 摘要

79.  Mahant N, McCusker EA, Byth K, et al. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003 Oct 28;61(8):1085-92.

• 摘要

80.  Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease. Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012 Aug 7;79(6):597-603.

• 全文
• 摘要

81.  Reilmann R. Pharmacological treatment of chorea in Huntington's disease - good clinical practice versus evidence-based guideline. Mov Disord. 2013 Jul;28(8):1030-3.

• 全文
• 摘要

82.  Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96.

• 摘要

83.  Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012 Jul;34(7):1487-504.

• 摘要

84.  Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006 Feb 14;66(3):366-72.

• 摘要

85.  Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009 Dec 18;9:62.

• 全文
• 摘要

86.  Lucetti C, Gambaccini G, Bernardini S, et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci. 2002 Sep;23 Suppl 2:S83-4.

• 摘要

87.  Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2003 Jun 24;60(12):1995-7.

• 摘要

88.  Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002 Sep 10;59(5):694-9.

• 摘要

89.  Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003 Dec 9;61(11):1551-6.

• 摘要

90.  Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2004 Aug 10;63(3):597-8.

• 摘要

91.  Reuter I, Hu MT, Andrews TC, et al. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):238-41.

• 全文
• 摘要

92.  Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):577-9.

• 全文
• 摘要

93.  Bird MT, Paulson GW. The rigid form of Huntington's chorea. Neurology. 1971 Mar;21(3):271-6.

• 摘要

94.  Li Y, Hai S, Zhou Y, et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev. 2015 Mar 3;(3):CD009444.

• 全文
• 摘要

95.  Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord. 2014 Mar;29(3):401-5.

• 摘要

96.  Khalil H, Quinn L, van Deursen R, et al. What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study. Clin Rehabil. 2013 Jul;27(7):646-58.

• 摘要

97.  Cook C, Page K, Wagstaff A, et al; European Huntington’s Disease Network. Occupational therapy for people with Huntington’s disease: best practice guidelines. Jan 2012 [internet publication].

• 全文

98.  Quinn L, Busse M; European Huntington’s Disease Network. Physiotherapy clinical guidelines for Huntington’s disease. Neurodegen Dis Manage. 2012;2(1):21-31.

• 全文

99.  Hamilton A, Ferm U, Heemskerk AW, et al; European Huntington’s Disease Network. Management of speech, language and communication difficulties in Huntington’s disease. Neurodegen Dis Manage. 2012;2(1):67-77.

• 全文

100.  Brotherton A, Campos L, Rowell A, et al; Nutritional management of individuals with Huntington’s disease: nutritional guidelines. Neurodegen Dis Manage. 2012;2(1):33-43.

• 全文

101.  Frank S, Stamler D, Sung V, et al. Deutetrabenazine effect on total motor score in patients with Huntington disease (First-HD) (S27.008). Neurology. 2016 Apr 5;86(16 Suppl):S27.008.

• 全文

102.  Claassen D, Frank S, Stamler D, et al. Rating swallowing function in patients with Huntington disease enrolled in the First-HD study (S25.006). Neurology. 2016 Apr 5;86(16 Suppl):S25.006.

• 全文

103.  ClinicalTrials.gov. A clinical study in subjects with Huntington's disease to assess the efficacy and safety of three oral doses of laquinimod (LEGATO-HD). Mar 2018 [internet publication].

• 全文

104.  University College London. UCL news: drug lowers deadly Huntington's disease protein. Dec 2017 [internet publication].

• 全文

105.  de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011 Dec;10(12):1049-57.

• 摘要

106.  Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2013 Sep;28(10):1407-15.

• 摘要

107.  Rodrigues FB, Wild EJ. Clinical trials corner: September 2017. J Huntingtons Dis. 2017;6(3):255-63.

• 全文
• 摘要

108.  ClinicalTrials.gov. A study evaluating if pridopidine is safe, efficacious, and tolerable in patients with Huntington's disease (Open PRIDE-HD) (NCT02494778). Dec 2017 [internet publication].

• 全文

109.  Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015 Jan;14(1):39-47.

• 摘要

110.  Raptor Pharmaceuticals. News release: Raptor Pharmaceuticals announces phase 2/3 clinical trial results with cysteamine (RP103) in Huntington’s disease. Novato, CA: Raptor Pharmaceuticals, 2014.

111.  Reilmann R, Squitieri F, Priller J, et al. Safety and tolerability of selisistat for the treatment of Huntington’s disease: results from a randomized, double-blind, placebo-controlled phase II trial (S47.004). Neurology. 2014 Apr 8;82(10 Suppl):S47.004.

• 全文

112.  Niccolini F, Haider S, Reis Marques T, et al. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain. 2015 Oct;138(Pt 10):3016-29.

• 全文
• 摘要

113.  Beaumont V, Zhong S, Lin H, et al. Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington's disease models. Neuron. 2016 Dec 21;92(6):1220-37.

• 全文
• 摘要

114.  Group HS. Brief report: Pfizer Amaryllis trial ends: negative results lead to termination of extension study. 2016 [internet publication].

• 全文

115.  Hunt VP, Walker FO. Dysphagia in Huntington's disease. J Neurosci Nurs. 1989 Apr;21(2):92-5.

• 摘要

116.  Hamilton JM, Wolfson T, Peavy GM, et al; Huntington Study Group. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):209-12.

• 全文
• 摘要

117.  Trejo A, Tarrats RM, Alonso ME, et al. Assessment of the nutrition status of patients with Huntington's disease. Nutrition. 2004 Feb;20(2):192-6.

• 摘要

118.  Wheelock VL, Tempkin T, Marder K, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003 Mar 25;60(6):998-1001.

• 摘要

119.  van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009 Aug;8(8):765-74.

• 摘要

120.  Djoussé L, Knowlton B, Cupples LA, et al. Weight loss in early stage of Huntington's disease. Neurology. 2002 Nov 12;59(9):1325-30.

• 摘要

121.  Robins Wahlin TB, Bäckman L, Lundin A, et al. High suicidal ideation in persons testing for Huntington's disease. Acta Neurol Scand. 2000 Sep;102(3):150-61.

• 摘要

122.  Di Maio L, Squitieri F, Napolitano G, et al. Suicide risk in Huntington's disease. J Med Genet. 1993 Apr;30(4):293-5.

• 全文
• 摘要

123.  Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986 Jun;24(2):305-11.

• 摘要

124.  Skegg K. Self-harm. Lancet. 2005 Oct 22-28;366(9495):1471-83.

• 摘要

125.  Conner KR, Duberstein PR, Conwell Y, et al. Psychological vulnerability to completed suicide: a review of empirical studies. Suicide Life Threat Behav. 2001 Winter;31(4):367-85.

• 摘要

126.  Lantz MS. Suicide in late life. Identifying and managing at-risk older patients. Geriatrics. 2001 Jul;56(7):47-8.

• 摘要

127.  Shenassa ED, Rogers ML, Spalding KL, et al. Safer storage of firearms at home and risk of suicide: a study of protective factors in a nationally representative sample. J Epidemiol Community Health. 2004 Oct;58(10):841-8.

• 全文
• 摘要

128.  Gorlyn M. Impulsivity in the prediction of suicidal behavior in adolescent populations. Int J Adolesc Med Health. 2005 Jul-Sep;17(3):205-9.

• 摘要

129.  Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20.

• 摘要